| Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial | JAMA | 10/08/26 | High - A large, well-designed negative trial for the NAD+ precursor thesis in neurodegeneration. It directly undercuts disease-modifying claims for nicotinamide riboside in Parkinson disease and is a headwind for NAD+ supplement and clinic businesses that market healthspan benefits, including Niagen Bioscience (the former ChromaDex) and wellness chains selling NAD+ treatments; it does not test aging endpoints or healthy people, and one trial does not rule out other NAD+ strategies. |
| A systems-level dissection of aging and longevity mechanisms powered by an evidence-routed AI knowledge graph | Scientific Reports | 10/06/26 | Low to Medium - A research-support tool rather than a biological finding: it shows how literature and database knowledge on aging can be organized for hypothesis generation, with evidence traceability that is good (97.3%) but claim support that is only moderate (65.3%), so outputs still need expert checking. Relevant to AI-for-aging companies and to anyone building discovery tools, in the same space as LongevityBench; it does not report a target or therapy. |
| A new blue zone? exceptional late-life survival in Bolotana, Sardinia | Frontiers in Aging | 10/05/26 | Low - A demographic brief report from a small population using recent records, with a period-dependent advantage the authors themselves flag as unconfirmed. It is a candidate for longevity-population research rather than anything investable, and it identifies no mechanism or intervention. |
| TMEM174 deficiency reduces longevity by promoting phosphate-driven vascular calcification | Scientific Reports | 10/02/26 | Low - A mouse study linking phosphate handling in the kidney to lifespan and vascular calcification. It adds support to phosphate load as a modifiable aging-related risk factor and names a possible drug target, but it is early, preclinical, and does not report a therapy. |
| High-protein diet promotes aging by activating the CG6415/AMT gene and disrupting mitochondrial homeostasis | Journal of Advanced Research | 10/01/26 | Low to Medium - A fly and cell-culture study that adds a mechanism (a gene that links high protein intake to mitochondrial dysfunction and p53-p21 senescence signaling) to the debate over protein intake and aging. It has no human outcome data, so it does not settle dietary advice, but it names a candidate pathway and target, AMT, that may interest nutrition-focused longevity companies. |
| Deep learning perturbation models can outperform baselines on calibrated metrics | Nature Biotechnology | 10/01/26 | Low to Medium - A methods paper on how to evaluate AI models that predict cell responses to genetic perturbations. It does not report a therapy or target, but it bears on how much to trust claims from AI virtual-cell and perturbation-prediction companies, including those working on cell reprogramming and aging. |
| X and Y chromosomes as determinants of aging and disease | Science | 10/01/26 | Medium - A high-profile synthesis rather than new data, but it makes the case that sex should be treated as a biological variable in aging research, including trial design and biomarker development. That bears on how longevity trials are stratified and powered, and on whether therapies need sex-specific dosing or targets. It reports no therapeutic result. |
| Autologous iPSC-Derived Cell Therapy for Parkinson's Disease: Preclinical Evaluation through Genomic Quality Controls | Cell Stem Cell | 10/01/26 | Medium - The paper supports the manufacturing consistency and safety package behind a patient-specific cell therapy that the company says is moving from a Phase 1/2a trial toward Phase 3, which matters for judging whether autologous iPSC products can be made reliably at scale. The data are preclinical and company-reported; the paper does not itself show clinical benefit. |
| Joint impact of premature age at menopause and depression on mortality in older females: an NHANES analysis | Menopause | 09/29/26 | Low to Medium - Supports the case that early loss of ovarian function is a marker of higher mortality risk and that depression compounds it, which bears on women's-longevity screening, hormone-therapy and mental-health programs for women with early menopause. The combined estimate rests on a small group (wide interval) and the design is observational, so it justifies attention to this group rather than any specific intervention. |
| Joint association of leukocyte telomere length and muscle mass with mortality: a longitudinal nationwide population-based study | Nutrition & Metabolism | 09/25/26 | Relevant to any company building composite aging-biomarker panels: provides evidence that combining telomere length and muscle mass measurements yields more nuanced risk stratification than either alone, with concrete, demographic-specific hazard ratios usable for product positioning or clinical protocol design - particularly the finding that risk drivers differ meaningfully by age and sex, which argues against a one-size-fits-all composite score. |